Immunome to Present at H.C. Wainwright Conference Amid Key Pipeline Developments — Immunome, Inc.

Event summary

Immunome to present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.
Company's pipeline includes varegacestat (NDA accepted by FDA), IM-1021 (ROR1 ADC), IM-1617 (solid tumor ADC), and IM-3050 (FAP-targeted radioligand therapy).
Management team has deep experience in antibody-drug conjugate development and commercialization.
Webcast replay available for 30 days post-presentation.

The big picture

Immunome's presentation comes as the targeted oncology space faces increasing competition and regulatory scrutiny. The company's focus on first-in-class and best-in-class therapies positions it within a niche, but its ability to differentiate will be critical. With multiple clinical-stage assets, Immunome is betting on a diversified approach to capture value in the rapidly evolving cancer treatment landscape.

What we're watching

Regulatory Progress: How the FDA's acceptance of the varegacestat NDA will impact Immunome's timeline for commercialization.
Pipeline Execution: Whether Immunome can sustain momentum across its diverse ADC and radioligand therapy programs.
Investor Sentiment: The pace at which Immunome can convert pipeline progress into market valuation gains.